clinical trial · NCT06694298
A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·phase1·not yet recruiting·n = 50
Refractory Active Systemic Lupus ErythematosusSYS6020
brief summary
This study aimed to observe the safety and tolerability of SYS6020 in adult participants with refractory active systemic lupus erythematosus, determine the recommended dose (RD) that may be explored for subsequent studies, and preliminly evaluate the clinical efficacy of this product,and explore the pharmacokinetics and immunogenicity of SYS6020 injection in those participants.
started
Dec 26, 2024
primary completion
Jan 29, 2029
completion
Jan 29, 2029
last updated
Nov 19, 2024
official title
A Phase I Clinical Study of BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection in Refractory Active Systemic Lupus Erythematosus Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol